Drug intelligence / Profile preview

vitexin

Development stage
Preclinical
Lead developer
Hospital of Traditional Medicine
Modality
Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Administration
Oral
01

Overview

Vitexin is a naturally occurring flavone glycoside, specifically apigenin 8-C-glucoside, found in various medicinal and food plants such as passion flower, bamboo leaves, and pearl millet. It exhibits a wide range of pharmacological effects including antioxidant, anti-inflammatory, anticancer (antineoplastic), antinociceptive (pain-relieving), neuroprotective, anxiolytic (anxiety-reducing), anticonvulsant, and platelet aggregation inhibitory activities. Mechanistically, vitexin acts through multiple pathways such as inhibition of alpha-glucosidase enzyme activity[1], modulation of GABAergic neurotransmission[5], suppression of oxidative stress via upregulation of antioxidant genes like Nuclear factor erythroid 2–related factor 2 (Nrf2) and Heme oxygenase 1 (HO-1)[6][7], inhibition of pro-inflammatory signaling pathways including p38 mitogen activated protein kinase (p38 MAPK) and Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)[8], reduction in beta-amyloid formation by inhibiting Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) (β-secretase)[6], and protection against neurodegeneration. Vitexin is under investigation for its potential use in neurological disorders (such as epilepsy and anxiety), cancer prevention/treatment, cardiovascular protection under high glucose conditions (e.g., diabetes-related vascular inflammation), memory impairment, cerebral ischemia/reperfusion injury, myocardial injury, respiratory injury due to oxidative stress-related diseases[4][5][6][7][8]. It is not an approved pharmaceutical drug but is considered investigational or used as a dietary supplement ingredient.

Other names
apigenin 8-C-glucosideapigenin8-C-glucosideapigenin-8-C-glucoside
02

Targets

MAPK14 (p38 mitogen-activated protein kinase alpha)Sucrase-IsomaltaseNFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)BACE1 (Beta-site APP-cleaving enzyme 1)HMOX1 (Heme oxygenase 1)NF-κBGABRA2 (Gamma-aminobutyric acid receptor subunit alpha 2)Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on vitexin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on vitexin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call